Principal Investigator On
ANBL1531-JDI- A Phase III Study of 131I Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL),”
awarded by PUBLIC HEALTH INSTITUTE (PHI)
APEC1621I -NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes
awarded by PUBLIC HEALTH INSTITUTE (PHI)
ARST1921, A Safety, Pharmacokinetic and Efficacy Study of a ?-Secretase Inhibitor, Nirogacestat(PF 03084014; IND# 146375), in Children and Adolescents with Progressive, Surgically Unresectable Desmoid Tumors -AR10441
awarded by PUBLIC HEALTH INSTITUTE (PHI)
ARST1921, A Safety, Pharmacokinetic and Efficacy Study of y-Secretase Inhibitor, Nirogacestat (PF03084014:IND# 146375), in Children and Adolescents with Progressive, Surgically Unresectable Desmoid Tumors
awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
MCC 18613 Phase II Study of nab-Paclitaxel in Combination with Gemcitabine for Treatment of Recurrent/Refractory Sarcoma in Teenagers and Young Adults
awarded by H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE
MCC 20320 Blood Based Biomarkers for Minimal Residual Disease Detection in Pediatric Sarcomas
awarded by H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE
Multi-Institutional Retrospective Review of Infantile Sarcomas with Internal Tandem Duplication of BCOR
awarded by CHILDREN'S HOSPITAL MEDICAL CENTER (CINCINNATI)
NIH National Clinical Trials Network (NCTN) Grant (2U10CA180886) Successor to NIH National Clinical Trials Network (NCTN Grant (U10CA180886)
awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
NIH National Clinical Trials Network (NCTN) Grant (2U10CA180886) Successor to NIH National Clinical Trials Network (NCTN Grant (U10CA180886)
awarded by PUBLIC HEALTH INSTITUTE (PHI)
National Clinical Trials Network (NCTN) Grant (U10CA180886) Study Chair
awarded by PUBLIC HEALTH INSTITUTE (PHI)
Phase 1-11 Study of MEK 162 for Children with Progressive or Recurrent Cancer and A Phase 11 Study of Children with Low- Grade Gliomas and Other Ras/ RAF/MAP Pathway Activated Tumors
awarded by CHILDREN'S HOSPITAL LA
Private Grant
awarded by UNITED THERAPEUTICS CORPORATION
Private Grant
awarded by CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY - DBA ATRIUM HEALTH
Private Grant
awarded by CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY - DBA ATRIUM HEALTH
Private Grant
awarded by CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY - DBA ATRIUM HEALTH
Private Grant
awarded by CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY - DBA ATRIUM HEALTH